MAPT and supranuclear palsy, progressive, 1: A similar observation was made by Smith et al. [113] in a case of PSP, where they found that the density of tau pathology on immunostaining correlated with in vivo metabolism (measured with [18F]FDG PET) but not with in vivo [18F]AV-1451 binding.